Onconetix (NASDAQ:ONCO - Get Free Report) was upgraded by equities research analysts at Wall Street Zen to a "hold" rating in a research note issued on Saturday.
Onconetix Stock Performance
ONCO stock opened at $4.73 on Friday. Onconetix has a 52-week low of $4.27 and a 52-week high of $1,190.00. The stock's 50 day moving average is $6.11 and its two-hundred day moving average is $25.39.
Onconetix (NASDAQ:ONCO - Get Free Report) last posted its quarterly earnings data on Thursday, June 12th. The company reported $21.25 earnings per share (EPS) for the quarter. The business had revenue of $0.10 million for the quarter.
Institutional Investors Weigh In On Onconetix
A hedge fund recently bought a new stake in Onconetix stock. Geode Capital Management LLC purchased a new stake in Onconetix, Inc. (NASDAQ:ONCO - Free Report) in the fourth quarter, according to its most recent filing with the SEC. The fund purchased 55,418 shares of the company's stock, valued at approximately $35,000. Geode Capital Management LLC owned about 0.67% of Onconetix at the end of the most recent quarter. 23.89% of the stock is currently owned by institutional investors and hedge funds.
About Onconetix
(
Get Free Report)
Onconetix, Inc, a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Onconetix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Onconetix wasn't on the list.
While Onconetix currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
